Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metlife (MET) Notes Payables (2016 - 2026)

Metlife's Notes Payables history spans 18 years, with the latest figure at $404.0 million for Q1 2026.

  • Quarterly Notes Payables rose 6.04% to $404.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $404.0 million through Mar 2026, up 6.04% year-over-year, with the annual reading at $355.0 million for FY2025, 23.66% down from the prior year.
  • Notes Payables came in at $404.0 million for Q1 2026, up from $355.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $465.0 million in Q4 2024 to a low of $119.0 million in Q4 2023.
  • The 5-year median for Notes Payables is $323.0 million (2022), against an average of $282.8 million.
  • Year-over-year, Notes Payables crashed 50.13% in 2022 and then surged 290.76% in 2024.
  • Metlife's Notes Payables stood at $175.0 million in 2022, then tumbled by 32.0% to $119.0 million in 2023, then soared by 290.76% to $465.0 million in 2024, then dropped by 23.66% to $355.0 million in 2025, then increased by 13.8% to $404.0 million in 2026.
  • Per Business Quant, the three most recent readings for MET's Notes Payables are $404.0 million (Q1 2026), $355.0 million (Q4 2025), and $378.0 million (Q3 2025).